Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treat-and-Extend Aflibercept for Diabetic Macular Edema
KCT0007542Phase 4Recruiting
- Sponsor
- Bayer
- Start
- Jun 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in diabetic macular edema (DME), sponsored by Bayer. Started Jun 2022; status: recruiting.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on KCT0007542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007542.